Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2012

Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, et al. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012;7(6):e38881.

Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209(9):1537-51.

Goyal A, Baloch ZW. Fine needle aspiration of vagal paraganglioma: an interesting clinical presentation. Diagn Cytopathol. 2012;40(7):651-2.

Cushing M, Kawaguchi K, Friedman KD, Mark T. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion. 2012;52(7):1535-41.

Zhao Z, Zhao Q, Warrick J, Lockwood CM, Woodworth A, Moley KH, et al. Circulating microRNA miR-323-3p as a biomarker of ectopic pregnancy. Clin Chem. 2012;58(5):896-905.

Kim J, Kim W-, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle. 2012;11(6):1123-30.

Pachydaki SI, Jakobiec FA, Bhat P, Sobrin L, Michaud NA, Seshan SV, et al. Surgical management and ultrastructural study of choroidal neovascularization in punctate inner choroidopathy after bevacizumab. J Ophthalmic Inflamm Infect. 2012;2(1):29-37.

Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012;120(5):1095-106.

Kim J, Keay SK, You S, Loda M, Freeman MR. A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2. PLoS One. 2012;7(12):e50392.

Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep. 2012;13(2):122-35.